Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Proteomic profiling of sporadic late-onset nemaline myopathy
Neuromuscular and Clinical Neurophysiology (EMG)
P15 - Poster Session 15 (5:30 PM-6:30 PM)
11-001

SLONM is characterized by accumulation of nemaline rods in muscles without any significant inflammation. It is commonly associated with a monoclonal protein (MP) and responds to treatment with intravenous immunoglobulins or autologous stem-cell transplantation. However, underlying disease mechanisms remain unknown.

 

To define the proteomic profile of sporadic late-onset nemaline myopathy (SLONM) and explore its pathogenesis.

 

We performed label-free liquid chromatography mass spectrometry on laser-dissected frozen muscle samples from 5 patients with SLONM, 3 with an associated monoclonal protein (MP), and 4 controls, to determine the proteomic profile, focusing on immune-related proteins and the immunoglobulin light chain variable regions. 

294 proteins were differentially expressed, 272 upregulated and 22 downregulated. Among the top 100 upregulated proteins, the most common categories were as follows: nuclear/nucleic acid metabolism (24%), extracellular matrix/basal lamina (17%), immune response (13%), and actin dynamics (8%). Downregulated proteins consisted mostly of contractile proteins. Among all upregulated proteins, there were 65 related to the immune system, including 8 proteins involved in MHC1 complex and antigen processing, 15 in MHCII complex and phagocytosis, and 23 in B and/or T cell function. Among 9 upregulated immunoglobulin proteins, there were 2 light chain variable region genes. However, these were also detected in SLONM cases without an MP, and there was no evidence of clonally-dominant immunoglobulin deposition in SLONM-MP.  Increased MHC1 reactivity was present in fibers containing nemaline rods as well as adjacent non-atrophic fibers.

Various categories of upregulated proteins are found in muscle tissue in SLONM. Our findings suggest that aberrant immune activation is present in this disease, but do not support a direct causal relationship between the MP and SLONM.
Authors/Disclosures
Elie Naddaf, MD (Mayo Clinic)
PRESENTER
Dr. Naddaf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Expert Connect. The institution of Dr. Naddaf has received research support from NIAMS. The institution of Dr. Naddaf has received research support from American Neuromuscular Foundation. The institution of Dr. Naddaf has received research support from Fulcrum therapeutics. The institution of Dr. Naddaf has received research support from Abcuro. The institution of Dr. Naddaf has received research support from Cabaletta .
Surendra Dasari No disclosure on file
Duygu Selcen, MD, FAAN (Mayo Clinic) Dr. Selcen has nothing to disclose.
No disclosure on file
No disclosure on file
Michelle L. Mauermann, MD, FAAN (Mayo Clinic) The institution of Dr. Mauermann has received research support from IONIS. The institution of Dr. Mauermann has received research support from Alnylam. Dr. Mauermann has received publishing royalties from a publication relating to health care.
No disclosure on file